+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cerebral Palsy Market 2021-2025

  • PDF Icon

    Report

  • 120 Pages
  • January 2022
  • Region: Global
  • TechNavio
  • ID: 5547322
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the cerebral palsy market and it is poised to grow by $961.91 mn during 2021-2025, progressing at a CAGR of 5.45% during the forecast period. The report on the cerebral palsy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising incidence of cerebral palsy and increasing awareness about cerebral palsy.

The cerebral palsy market analysis includes the product segment and geographic landscape.

The cerebral palsy market is segmented as below:


By Product

  • Anticonvulsant drugs
  • Antispastic drugs
  • Anticholinergic drugs
  • NSAIDs
  • Antidepressants and others

By Geographical Landscape

  • North America
  • Asia
  • Europe
  • ROW

This study identifies the high patient dependence on medications for cerebral palsy as one of the prime reasons driving the cerebral palsy market growth during the next few years.

The report on cerebral palsy market covers the following areas:

  • Cerebral palsy market sizing
  • Cerebral palsy market forecast
  • Cerebral palsy market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cerebral palsy market vendors that include AbbVie Inc., Acorda Therapeutics Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Johnson and Johnson Inc., Medtronic Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Also, the cerebral palsy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Parent Market
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Anticonvulsant drugs - Market size and forecast 2020-2025
  • Antispastic drugs - Market size and forecast 2020-2025
  • Anticholinergic drugs - Market size and forecast 2020-2025
  • NSAIDs - Market size and forecast 2020-2025
  • Antidepressants and others - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape
  • Overview

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity By Geographical Landscape

Drivers, Challenges, and Trends
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Landscape disruption
  • Competitive landscape

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Johnson and Johnson Inc.
  • Medtronic Plc
  • Pfizer Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research Methodology
  • List of abbreviations

List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Product - Market share 2020-2025 (%)
  • Comparison by Product
  • Anticonvulsant drugs - Market size and forecast 2020-2025 ($ million)
  • Anticonvulsant drugs - Year-over-year growth 2020-2025 (%)
  • Antispastic drugs - Market size and forecast 2020-2025 ($ million)
  • Antispastic drugs - Year-over-year growth 2020-2025 (%)
  • Anticholinergic drugs - Market size and forecast 2020-2025 ($ million)
  • Anticholinergic drugs - Year-over-year growth 2020-2025 (%)
  • NSAIDs - Market size and forecast 2020-2025 ($ million)
  • NSAIDs - Year-over-year growth 2020-2025 (%)
  • Antidepressants and others - Market size and forecast 2020-2025 ($ million)
  • Antidepressants and others - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Product
  • Customer landscape
  • Market share By Geographical Landscape 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity By Geographical Landscape ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Key customers
  • AbbVie Inc. - Segment focus
  • Acorda Therapeutics Inc. - Overview
  • Acorda Therapeutics Inc. - Business segments
  • Acorda Therapeutics Inc. - Key offerings
  • Acorda Therapeutics Inc. - Key customers
  • Acorda Therapeutics Inc. - Segment focus
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Business segments
  • Eli Lilly and Co. - Key offerings
  • Eli Lilly and Co. - Key customers
  • Eli Lilly and Co. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • GW Pharmaceuticals Plc - Overview
  • GW Pharmaceuticals Plc - Business segments
  • GW Pharmaceuticals Plc - Key offerings
  • GW Pharmaceuticals Plc - Key customers
  • GW Pharmaceuticals Plc - Segment focus
  • Johnson and Johnson Inc. - Overview
  • Johnson and Johnson Inc. - Business segments
  • Johnson and Johnson Inc. - Key offerings
  • Johnson and Johnson Inc. - Key customers
  • Johnson and Johnson Inc. - Segment focus
  • Medtronic Plc - Overview
  • Medtronic Plc - Business segments
  • Medtronic Plc - Key offerings
  • Medtronic Plc - Key customers
  • Medtronic Plc - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Teva Pharmaceutical Industries Ltd. - Overview
  • Teva Pharmaceutical Industries Ltd. - Business segments
  • Teva Pharmaceutical Industries Ltd. - Key offerings
  • Teva Pharmaceutical Industries Ltd. - Key customers
  • Teva Pharmaceutical Industries Ltd. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global cerebral palsy market: AbbVie Inc., Acorda Therapeutics Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Johnson and Johnson Inc., Medtronic Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is high patient dependence on medications for cerebral palsy.'

According to the report, one of the major drivers for this market is the rising incidence of cerebral palsy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Johnson and Johnson Inc.
  • Medtronic Plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.